Acadia Pharmaceuticals Inc. is a rising star in the biopharmaceutical industry, with a sharp focus on developing and commercializing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company's flagship product, NUPLAZID (pimavanserin), is a game-changer in the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. But that's just the beginning: Acadia's pipeline includes Trofinetide, a groundbreaking new treatment for Rett Syndrome, as well as Pimavanserin, currently undergoing Phase III clinical trials to treat the negative symptoms of schizophrenia, and ACP-204 for Alzheimer's disease psychosis. Acadia is also pursuing several other promising programs for neuropsychiatric symptoms, including antisense oligonucleotide programs. The company has taken a collaborative approach to its R&D efforts, forging partnerships with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications, as well as with Stoke Therapeutics, Inc. to discover, develop and market novel RNA-based therapies for severe and rare genetic neurodevelopmental diseases of the CNS. Founded in 1993 as Receptor Technologies, Inc., Acadia Pharmaceuticals has come a long way since those early days. The company is now headquartered in San Diego, California, and is making waves in the biopharmaceutical industry with its innovative and life-changing treatments for CNS disorders and rare diseases.